α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

By B. Mollenhauer, J. Locascio, W. Schulz-Schaeffer, F. Sixel-Döring, C. Trenkwalder, M. Schlossmacher. Lancet Neurology, 2011

614 citations recorded by the source corpus.

Subfields: Neurology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders (2011, background): “Furthermore, tau and α - synuclein have been measured at robust levels in the cerebrospinal fluid, suggesting secretion of these proteins in vivo 91 .”
α-Synuclein in Parkinson's disease. (2012, background): “…fluid (CSF), most studies appear to show a reduction of total a-synuclein levels in PD patients compared with controls (Tokuda et al. 2006; Mollenhauer et al. 2008, 2011; Hong et al. 2010; Kasuga et al. 2010); in fact, a comprehensive study suggested thata-synuclein levels, measured by a…”
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “There are no clinically available laboratory biomarkers (CSF, serum, or urine) that aid in diagnosing DLB or PDD, although CSF a-synuclein may be a potential biomarker (Mollenhauer et al. 2011).”